Announcements Trials
Browse Landscape

Phase

Phase 2 69Phase 1 19Phase 1/2 12Phase 3 9Phase 2/3 5Phase NA 2Phase EARLY_PHASE1 1

Status

Unknown 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 36Thoracic 20Head & Neck 17Gynecologic 9Genitourinary 5Breast 5Other solid neoplasm 4Tumor-Agnostic 2Sarcoma 2Lymphoid 1CNS 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 1Inflammatory Breast Neoplasms 1Carcinoma, Ductal, Breast 1

Interventions

Capecitabine 17Paclitaxel 16Docetaxel 13Carboplatin 12Cyclophosphamide 11Gemcitabine 9Epirubicin 9Trastuzumab 8Letrozole 8Doxorubicin 7pertuzumab 5Cisplatin 5Vinorelbine 4130-nm albumin-bound paclitaxel 4exemestane 3Zoledronic Acid 3Tamoxifen 3Neoadjuvant Therapy 3Lapatinib 3Injections 3Drug Therapy 3Ado-Trastuzumab Emtansine 3AC protocol 3pyrotinib 2palbociclib 2camrelizumab 2apatinib 2Thiotepa 2Taxes 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × Cisplatin × Breast × Clear all
NCT06268327 2024-02-20

Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy

Assiut University

Phase 2/3 Not yet recruiting
30 enrolled
Breast

Breast Neoplasms

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Fudan University

Phase 2/3 Active not recruiting
503 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02221999 2023-08-29

SHPD002

RenJi Hospital

Phase 2/3 Active not recruiting
250 enrolled
Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT03580395 2021-07-09

Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer

Hebei Medical University Fourth Hospital

Phase 2/3 Unknown
200 enrolled
Breast

Breast Neoplasms

NCT03423849 2018-02-06

The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy

Shandong Cancer Hospital and Institute

Phase 2/3 Unknown
200 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡